DATE: November 8, 2018
TIME: 11:00am EST, 5:00pm CET
Personalized and precision medicine are rapidly growing areas that require high quality spectral as well as metadata to categorize patients. Standardized spectral data are key to identify biomarkers or patterns of multiple biomarkers. Correct description of the natural variation in body fluids of healthy cohorts is the basis to correct outlier signal identification describing deviations from normality. Giving access to a large number of samples and spectroscopy data thereof is a task, that can be fulfilled by biobanks. Based on the reproducibility and transferability of nuclear magnetic resonance (NMR) multiple biobanks under standardization can deliver NMR spectra instead of Aliquots, to be used in clinical trials or clinical and translational research. Such NMR spectra can in first place be used for extensive quality control of biobank specimens and creating large amounts of quantification results e.g. in plasma/serum and urine. Such results can be stored with the metadata for each sample.
The Bruker IVDr Platform and embedded solutions for biobanking will be shortly introduced before Prof Nauck takes over and presents results obtained analyzing plasma/serum and urine NMR-spectral data generated under fully standardized condition in targeted and untargeted mode. It will also be shown how lipoprotein subclass analysis and small molecule quantification in plasma/serum as well as quantification of urinary metabolites can support the development of diagnostic routines.
In addition, Prof. Nauck will highlight the need for high quality biobanking and the benefit of applying NMR analysis on biobank specimen. Providing access to fully standardized spectra produced as part of the biobank QC forms a major contribution to clinical and translational research.
Viewers can expect to see the following key topics:
Saving time and cost by providing NMR spectra under standardized conditions from each biobank sample as part of the QC and storing them into the biobank together with quantification results. Biobank clusters using the standardized NMR approach will rapidly grow, providing exchangeable spectra.
Development of potential new diagnostic methods under standardized NMR conditions, be it in precision medicine or using epidemiological approaches.
Who should attend:
The webinar will be of interest to biobanks, hospitals that have biorepositories, pharmaceutical companies in development and clinical trials, epidemiologist and laboratories that are interested in optimizing NMR spectroscopic techniques methods, which can contribute to a system biology approach.
Important note: The methods and solutions discussed during the webinar are for research use only and not for use in clinical diagnostic procedures